NCT03995875Completed
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLC.
Source: ClinicalTrials.gov · Last updated 5 Dec 2024
Brief summary (registry, in English)
This observational study is designed to assess the long term safety of the durvalumab treatment period including subsequent treatment period and demonstrate the efficacy of patients treated with durvalumab following chemoradiation therapy in the real world.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 529 (actual)
- First submitted
- 6 Jun 2019
- Start date
- 25 Jul 2019
- Primary completion date
- 11 Jan 2024
- Lead sponsor
- AstraZeneca
- Diseases
- Lung cancer, Childhood cancers
- NCT number
- NCT03995875
What you commit to
- Study type: Observational
- Participants enrolled: 529
- From 25 Jul 2019 to the primary completion date, 11 Jan 2024
- 43 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who would join any interventional clinical studies using unapproved drugs or off-label use of drugs from first diagnosis to the end of the durvalumab treatment
Age
- Age \< 20
Other
- Patients who would join Post Marketing Surveyllance for durvalumab.
Who the study is looking for
- Patients who receive durvalumab for unresectable stage III NSCLC at first time following chemoradiation therapy.
- Patients who provided written informed consent.
Sex: All · Does not accept healthy volunteers
Sites (43)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.